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The  term  Ergot  is  referred  to the  sclerotium  of  ascomycetes  – a protective  kernel  produced
during  resting  stage  of some  fungi  –  which  replaces  seeds  of susceptible  cereals  and  plants
intended for  human  and  animal  diet.  It contains  various  composition  of tryptophan-derived
toxins  deﬁned  ergot  alkaloids.  Since  sclerotia  can  be harvested  and  milled  together  with
cereals, they  represent  a source  of  food  and  feed  contamination  after breakage  and spread-
ing of  mycotoxins  into  the  various  milling  fractions.  The  effects  of  ergot  alkaloids,  including
those  adverse  for  human  health,  have  been  known  since  the Middle  Ages.  Nevertheless,
as  recently  stated  by the  European  Food  Safety  Authority,  further  information  is needed
on  metabolism  and  target  receptors-binding  of common  alkaloids  in  food.  Unfortunately,
the experimental  investigation  is  challenging  due  to the high  costs  in  terms  of time  and
money.  This  study  was thus  aimed  at assessing  whether  the in  silico  modeling  can  be an
effective  tool  to  investigate  the  interaction  between  multiple  serotonin  receptors  and  a
wide set  of  ergotamine  metabolites,  including  experimentally  detected  molecules  and  pre-
dicted derivatives.  Validated  models  provided  precious  insights  about  the  effects  exerted
by metabolic  modiﬁcations  on  the receptor–ligand  interaction.  Such  structural  information
may be useful  to support  the  design  of  further  experimental  analysis.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. Introduction
Ergot is the sclerotium of parasitic ascomycetes belong-
ng to the Claviceps genus that replaces the seeds of
usceptible host plants – traditionally rye and triticale, but
lso wheat, barley, millet and oats – and thus it can be
arvested together with cereals [1]. Besides lipids (40% in
eight), sclerotia contain a range of tryptophan-derived
oxins, known as “ergot alkaloids” (EAs). The total amount
nd the pattern of EAs signiﬁcantly vary between fungus
train, geographic regions and host plants [2]. Ergots can
e a relevant source of food and feed contamination as a
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consequence of the processing, mostly referable to grinding
processes, of ergot-containing cereals through the spread-
ing of alkaloids after sclerotia breakage [3]. EAs have long
been known as toxic compounds with a broad spectrum of
adverse effects on human and animal health leading mainly
to the ergotism disease. The ﬁrst well documented out-
break of ergotism dates back in the Middle Age – which
faded into witchcraft and folklore. Currently, it has been
recognized the occurrence of two illness forms, namely
gangrenous ergotism and convulsive ergotism [4]. The
former is responsible for several effects on the central ner-
vous system in the form of spasms, hallucinations and
epileptic ﬁts. The latter implies circulation disorders, and it
damages the poorly blood supplied parts of the body, such
as ﬁngers or toes. In the worst cases, the loss of damaged
parts may  occur due to tissue necrosis [5]. Interestingly, it is
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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commonly believed that the cognitive effects of ergotism
were at the base of several social troubles in the past, such
as the witch trials of Salem and the arising of mystic reli-
gious movements [6]. Nowadays it is known that EAs action
is mainly mediated by the interaction with -adrenergic,
dopaminergic and serotonergic receptors classes [4].
As recently stated by the European Food Safety Author-
ity (EFSA) [7], additional data on toxicokinetic and
toxicodynamic, including metabolism, of relevant EAs are
required. In particular, deeper studies about the compara-
tive target neurotransmitter receptor-binding activity are
needed. Furthermore, data on human metabolism of rele-
vant EAs in food and the toxicodynamic of their metabolites
are poor so far, even if paramount for the in-depth under-
standing of EAs action in living organisms. De facto, up
to date only few hydroxylated metabolites were identi-
ﬁed under in vitro conditions [8]. Moreover, even if it
is commonly believed that hepatic metabolites maintain
the activity of parent compounds, this hypothesis is actu-
ally based on data carried out on a unique metabolite
of dihydroergotamine [9]. As the experimental investi-
gation is hardly demanding in terms of costs and time,
the in silico modeling may  offer a fundamental support
in selecting lead compounds to be tested in workbench
trials. Within this framework, as a proof of concept, this
paper is focused on the interaction between some sero-
tonin receptors and the alkaloid ergotamine, which is one
of the most abundant ergopeptine alkaloid occurring in
food and feed [7,10], alongside a number of human metabo-
lites. Ergotamine consists of a natural d-lysergic acid (the
ergoline ring) linked to a tricyclic peptide by a peptide
bond (Fig. 1). The presence of a chiral center at C-8 deter-
mines the equilibrium between R and S epimers (-ine and
-inine forms, respectively), but the S isomer is considered
devoid of activity and only the -ine form is of biological rel-
evance [11]. Therefore, the present work mainly aimed at
assessing whether a straightforward computational proce-
dure – whose reliability to evaluate the bioactivity of small
molecules was already proved [12–15] – could be used to
investigate the interaction of ergoline-related compounds
with 5-hydroxy-triptamine receptors 2A, 2B and 2C (i.e.
5HT-2A, 5TH-2B and 5HT-2C, respectively). Then, it was
proposed the activity proﬁling of both putative and exper-
imentally detected ergotamine metabolites in respect of
such receptors. The work-ﬂow mainly involved: (i) the
homology modeling of 5HT-2A and 5HT-2C models on the
basis of the crystallographic structure of 5HT-2B; (ii) the
analysis of sequences and pocket anatomy; (iii) the train-
ing procedure on 5HT-2A, 5HT-2B and 5HT-2C models by
using ad hoc training-set; (iv) the assessment of proce-
dural performance by comparing results of GOLD–HINT
coupling with those obtained by using other benchmark
software; (v) the screening of queries-set on validated
models.
Whereas the effects on the binding to receptors exerted
by structural changes on the ergoline ring have been
already accounted (e.g. ref. [16,17]), to the best of our
knowledge, the present paper addressed for the ﬁrst
time the effect of metabolic modiﬁcations toward sero-
tonergic activity of such a wide range of ergotamine’s
human metabolites. Speciﬁcally, structural insights wereports 2 (2015) 535–545
collected on the effect exerted by such modiﬁcations on the
molecular initiating event underlying serotonergic action.
Such structural information may  be useful to support the
design of further experimental trials.
2. Material and methods
2.1. Computational procedure and software
2.1.1. Homology modeling
The crystallographic structure of human 5HT-2B recep-
tor (PDB code 4IB4 [18]) was the template for the homology
modeling of 5HT-2A and 5HT-2C receptors. Among the
various receptors, they have been chosen due to the high-
est sequence identity respect to 5HT-2B. The fusion BRILL
domain was removed and only transmembrane domain
was  taken into account. All co-crystallized molecules, with
the only exception of ergotamine, were removed. The Mod-
eler software, version 9.10, was  used [19] and the option
to include the ligand ergotamine into the binding site was
chosen. Then, each model was  relaxed by performing a mild
local minimization (250 iterations using Powell algorithm)
within 5 A˚ around the ligand. Local pairwise alignments
were conducted by using the on-line tool EMBOSS-Water
Pairwise Sequence Alignment (http://www.ebi.ac.uk) and
Smith–Waterman algorithm was  chosen.
2.1.2. Molecular modeling
All protein structures and ligands were processed by
using the software Sybyl, version 8.1 (www.tripos.com). All
atoms were checked for atom- and bond-type assignments.
Amino- and carboxyl-terminal groups were set as pro-
tonated and deprotonated, respectively. Hydrogen atoms
were computationally added to the protein and energy-
minimized using the Powell algorithm whit a coverage
gradient of ≤0.5 kcal (mol A˚)−1 and a maximum of 1500
cycles.
2.1.3. Pharmacophore models
The ligand binding site was  deﬁned by using the
Flapsite tool of the FLAP (Fingerprint for Ligand And
Protein) software developed by Molecular Discovery Ltd
(http://www.moldiscovery.com) [20], while the GRID algo-
rithm [21] was  used to investigate the corresponding
pharmacophoric space. The DRY probe was  used to describe
the potential hydrophobic interactions, while the sp2
carbonyl oxygen (O) and the neutral ﬂat amino (N1)
probes were used to describe the hydrogen bond accep-
tor and donor capacity of the target, respectively. All
images were obtained using the software PyMol version
1.7 (http://www.pymol.org).
2.1.4. Docking simulations and re-scoring procedures
The coupling of GOLD, to perform docking simulations,
and HINT software, as re-scoring function, has been already
proved to be effectively able to evaluate the bioactiv-
ity of small molecules [12–15]. The docking simulations
of compounds were performed with the GOLD version
5.1 (CCDC; Cambridge, UK; http://www.ccd.cam.ac.uk). All
crystallographic waters and ligands were removed and 50
poses for each compound were generated. No constraints
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ere set up, and the explorable space was deﬁned in a
adius of 10 A˚ from the centroid of the binding pocket.
or each GOLD docking search, a maximum number of
00,000 operations were performed on a population of
00 individuals with a selection pressure of 1.1. Operator
eights for crossover, mutation, and migration were set
o 95, 95, and 10, respectively. The number of islands was
et to 5 and the niche to 2. The hydrogen bond distance
as set to 2.5 A˚ and the vdW linear cut-off to 4.0. Ligand
exibility options “ﬂip pyramidal N”, “ﬂip amide bonds”,
nd “ﬂip ring corners” were allowed. Each best scored
ose according to GOLD scoring function was re-scored
y HINT. The software HINT (Hydrophatic INTeraction)
22] was used as the re-scoring function on the basis of
revious studies attesting the higher reliability of HINT
coring with respect to other scoring functions, and its
uccessful use in the search for ligands for other targets,
s well as in the estimation of ligand binding free ener-
ies. More in details, the score provides the evaluation
f thermodynamic beneﬁts of protein–ligand interaction,
nd therefore low/negative scores indicate not apprecia-
le protein–ligand interactions [13–15,23–27]. GOLD uses
 Lamarckian genetic algorithm and scores may  slightly
hange from run to run. Therefore, in order to exclude
 non-causative categorization of compounds, we con-
ucted simulations in triplicate and the mean values are
eported.ompounds.
2.1.5. Docking simulations with AutoDock Vina
AutoDock Vina version 1.1.2 was  used [28]. The
explorable space was deﬁned in a box having 10 A˚ side
lengths from the centroid of the binding site. The maxi-
mum  number of binding mode to generate was set at 25 and
the maximum energy difference between the best binding
mode and the worst one displayed was set at 9.
2.1.6. Metabolites identiﬁcations
Phase I metabolites and glycosylated derivatives of
ergotamine were computed by using the two benchmark
software MetaSite (http://moldiscovery.com) [29,30] and
MetaPrint2D-React [31], respectively. In both predictions
human metabolism was  accounted and only ﬁrst genera-
tion metabolites were collected.
2.2. Data collection
Data were collected considering three well-deﬁned sets
– a training set and two query sets – composed as reported
below.
2.2.1. Training set
Molecular docking is widely used to predict novel
active compounds or to decipher the mode of action
of ligands versus a given protein. Currently, the capa-
bility to distinguish true ligands from false ligands
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lly deterFig. 2. Experimenta
(i.e. decoys) is a solid check to assess the reliability of
docking analysis and the efﬁcacy of scoring functions
[32]. More in details, the capability to maximize the total
amount of true positives and true negatives, avoiding
false positives and false negatives, is the ﬁnal endpoint
of each in silico model. Speciﬁcally, in the matter of
upstream screening of potential health-damaging com-
pounds, false negatives should be strictly avoided. In this
work the most of true ligands derived from repositories
Fig. 3. Computed mmined metabolites.
of GPCR Decoy Database (GDD) [33]. In addition, the
previously described ligands ergocornine, ergocristine
and ergosine were also included (Fig. 1A). All ligands
were checked for the activity through PubChem-BioAssay
database (http://pubchem.ncbi.nlm.nih.gov). With respect
to decoys set, the procedure herein proposed applies
much better when intraclass comparison is performed, as
stated by recent ﬁndings [34]. Therefore, the employment
of decoys structurally related to ergopeptine ligands is
etabolites.
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robative for procedural reliability. Unlikely, to the best of
ur knowledge, there are no data in the literature concern-
ng the lack of binding between ergopeptine alkaloids and
eceptors under analysis (with the only exception of -inine
orms, as aforementioned). For these reasons, the employ-
ent of knowledge-based virtual decoys was chosen
35]. Speciﬁcally, single-point mutagenesis experiments
n serotonin receptors revealed the residues involved in
rgotamine binding, and identiﬁed which lacking contacts
re responsible for the loss of interaction [36]. Such infor-
ation was thus used to modify ergotamine scaffold in
 semi-combinatorial fashion, in order to disrupt the key
ontacts. In addition to ergotaminine, the most structurally
elated compound found in DUD database [37] – that is an
xample of public repository of decoys – was also included
Fig. 1B).
.2.2. Experimentally determined query set
A total of 10 ergotamine metabolites arising from in vitro
xperiments were collected from the literature [8]. The set
ainly consisted of hydroxylated metabolites on the ring
, with the only exception of one molecule bearing such
ing opened (Fig. 2)..2.3. Computed query set
Data on human metabolism of ergotamine are scarce
o far. Albeit the few results found in the literature
ig. 5. The anatomy of binding sites. The shape of the binding sites is represented i
ite  regions for placing, respectively, hydrophobic, hydrogen-bond-acceptor, andre labeled in black, while boxes indicate residues composing the binding
provided precious contributions to the research, they can-
not be considered exhaustive. Thus, in the aim to more
exhaustively evaluate the effects of metabolism, a series
of putative conjugates and phase-I metabolites were col-
lected (Fig. 3). Although the simulation returned all the
mono-hydroxylated compounds already included in the
experimentally determined set, those were not further
considered.
3. Results
3.1. Sequence analysis and pocket anatomy
Overall the models of 5HT-2A and 5HT-2C respectively
showed 60% and 61% of sequence identity with 5HT-2B,
and 71% between themselves. At the level of ligand bind-
ing site – deﬁned in a radius of 5 A˚ around the ligand
and comprising 30 residues – 5HT-2A and 5HT-2C showed
66.7% and 70% of residues conservation respect to 5HT-
2B, whilst they had 74% of residues conservation between
themselves (Fig. 4). Overall the pharmacophoric analysis
of binding sites revealed quite similar anatomies and com-
parable physico-chemical characteristics since all pockets
shared a marked hydrophobic environment with few polar
patches, mainly favorable to receive hydrogen-bond donor
groups (Fig. 5). Nevertheless, some single-point mutations
determined slight changes mainly in the form of local shape
resizing (further information are reported below).
n mesh. The white, red and blue contours represent the favorable binding
 hydrogen-bond-donor groups.
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Table  1
Training set results and thresholds deﬁnitions.
Compounds 5HT-2A 5HT-2B 5HT-2C
Ligands
Ergocornine 130 234 −801*
Ergocristine 459 661 −1.11E+04*
Ergosine 482 234 387
Ergotamine 1004 820 1117
Lisuride 372 230 282
Lysergide 858 973 1083
Methylergonovine 487 463 412
Pergolide 861 364 450
Terguride 348 643 1221
Decoys
Decoy  01 −6075 −1046 −1454
Decoy 02 −6499 −9.08E+04 −1.22E+05
Decoy 03 −2938 −2827 −2059
Decoy 04 −30.04E+05 −3.21E+04 −5066
Decoy 05 −828 −2.27E+04 −1384
Decoy 06 −10.01E+04 −1.06E+07 −3421
Decoy 07 −1356 −4105 −877
Decoy 08 −4.69E+07 −1.24E+08 −4.34E+04
Decoy 09 −4.61E+11 −2.92E+09 −2261
ZINC79670178 −653 −464 −194
Ergotaminine −5.78E+04 −8.17e+07 −9.04E+04
Threshold 
* Non congruent records invalidating 5HT-2C model.
3.2. Training procedure
The training procedure mainly consisted into the empir-
ical setting of the HINT thresholds in order to categorize
ligands and decoys into two clusters. As reported in Table 1,
consistent cut-off scores were provided for 5HT-2A and
5HT-2B (130 and 230 HINT scores, respectively). Accord-
ingly, only interactions recording scores above the cut-off
value were considered. On the contrary, 5HT-2C model was
rejected due to the presence of two false negatives (namely,
ergocornine and ergocristine).
3.3. Validation of procedural performance
The consistence of procedural performance on 5HT-2A
and 5HT-2B models was assessed by comparing results
of GOLD–HINT coupling with those obtained by using the
native GOLD scoring function GOLDScore and one of the
most used benchmark docking software, namely AutoDock
Vina. Neither of them provided consistent results, and thus
the case-speciﬁc efﬁcacy of GOLD–HINT coupling was con-
ﬁrmed (Table 2, Fig. 6). In addition also the geometric
reliability was  established since the procedure was able
to well reproduce the crystallographic pose of ergotamine
within 5HT-2B model (with an RMSD of 0.3 A˚; Fig. 7).
3.4. Results of ergotamine metabolites
All the results of detected and calculated metabolites are
summarized in Table 3. All metabolites predicted as able to
interact with 5HT-2A and 5HT-2B occupied the pocket in a
fashion resembling the crystallographic pose of ergotamine
(Fig. 7), and in accordance to previous ﬁndings of ergot
derivatives [17]. Since the architecture of binding between
ergotamine and 5HT-receptors has been already described
elsewhere [18,36], it was not treated here again. Rather, we130 230 Rejected
discussed solely the effects exerted by metabolic modiﬁca-
tions – implying that the main interactions were conserved
– emphasizing inactivating effects and model-speciﬁc pat-
terns.
3.4.1. Experimentally determined metabolites
Concerning the interaction with 5HT-2A, hydroxylation
of the ergotamine G ring variably affects protein–ligand
interaction. In particular, the top of the pocket showed a
rigid alternation of polar and hydrophobic patches. The
mono-hydroxylated compounds DM-1, DM-2, DM-3, DM-
4, DM-5 and the di-hyroxylated compound DM-10 better
satisﬁed such pharmacophoric requirements. Conversely,
the rest of the di-hydroxylated compounds (i.e. DM-6, DM-
7, DM-8 and DM-9) were predicted as unable to interact
with the model mainly due to the improper distribution of
hydrophilic groups within the hydrophobic environment.
A completely different pattern was  observed for 5HT-2B,
since only DM-3 was predicted as able to interact. This can
be explained by the localized reduction of available volume
due to the G359Q mutation that does not allow a proper
positioning of hydroxyl groups (Fig. 8A).
3.4.2. Computed metabolites
None of the conjugated metabolites was predicted as
able to interact with the two  models, mainly as a result
of steric hindrance. The rest of metabolites, with the
exception of CM-11 and CM-17, were predicted as able
to interact with 5HT-2A model. The lack of interactions
was  respectively caused by the ergoline moiety’s struc-
tural stiffening (as a consequence of carbon–carbon bond
reduction) which neglected the pocket requirements (CM-
11), and by hydrophobic-polar interferences due to the
improper positioning of the hydroxyl group (CM-17). A
quite different pattern was  globally observed for 5HT-2B
where the putatively inactive compounds were, in addition
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Table  2
GOLD scores and AutoDock Vina scores of training set within 5HT-2A and -2B models.
Compounds 5HT-2A 5HT-2B
GOLD Score AutoDock Vina GOLD score AutoDock Vina
Ergocornine 51 −10.7 65 −10.6
Ergocristine 60 −9.5 75 −10.0
Ergosine 75 −11.6 71 −10.3
Ergotamine 78 −11.1 80 −11.3
Lisuride 46 −8.2 60 −8.0
Lysergide 54 −10.5 54 −10.0
Methylergonovine 71 −10.5 69 −9.8
Pergolide 56 −9.1 50 −8.7
Terguride 37 −8.3 42 −8.5
Decoy  01 23 −0.4 55 −1.3
Decoy  02 51 1.7 46 −7.3
Decoy  03 30 13.9 12 2.4
Decoy  04 52 −2.5 50 −6.5
Decoy  05 29 −3.2 32 −7.1
Decoy  06 23 6.1 6 −6.6
Decoy  07 30 5.4 35 1.0
Decoy  08 −1 4.0 12 −3.1
Decoiy 09 0 11.4 2 1.5
ZINC79670178 51 −10.5 49 −10.6
Ergotaminine 47 −7.8 45 −9.5
Table 3
Query sets results.
Compound 5HT-2A 5HT-2B
HINT score Expected interaction HINT score Expected interaction
Experimentally
detected
DM-1 669 Positive −598 Negative
DM-2  390 Positive −253 Negative
DM-3  414 Positive 700 Positive
DM-4  227 Positive 154 Negative
DM-5  234 Positive 3 Negative
DM-6  65 Negative −184 Negative
DM-7  −272 Negative −327 Negative
DM-8  46 Negative −258 Negative
DM-9  37 Negative −387 Negative
DM-10 326 Positive −807 Negative
Computational
prediction
CM-1  505 Positive 165 Negative
CM-2  659 Positive 268 Positive
CM-3  309 Positive 269 Positive
CM-4  401 Positive 457 Positive
CM-5  1113 Positive 783 Positive
CM-6  602 Positive 371 Positive
CM-7  688 Positive 383 Positive
CM-8  976 Positive 811 Positive
CM-9  534 Positive −285 Negative
CM-10 643 Positive 372 Positive
CM-11 118 Negative −908 Negative
CM-12 361 Positive −430 Negative
CM-13 497 Positive 463 Positive
CM-14 287 Positive 622 Positive
CM-15 418 Positive 458 Positive
CM-16 458 Positive 395 Positive
CM-17 −976 Negative 167 Negative
CM-18 740 Positive 657 Positive
CM-19 −3.5E+03 Negative −5487 Negative
egative
egative
egative
t
C
w
t
2CM-20 −7205 N
CM-21 −4913 N
CM-22 −7260 N
o CM-11 and CM-17, CM-1, CM-9 and CM-12. CM-9 and
M-12 shared hydroxylation at the level of ergoline moiety
hich occupied the buried portion of the pocket. Therefore,
he local shape reorganization between 5HT-2A and 5HT-
B at the bottom of the pocket, due to A225S and M218V −2786 Negative
 −2E+05 Negative
 −4703 Negative
mutations, may  partially explain these results (Fig. 8B).
On the contrary, CM-1 – that held para-hydroxylation on
phenylalanine side chain – was  predicted as inactive due to
pocket shape resizing and pharmacophoric switch caused
by D147K mutation at the top of the pocket (Fig. 8C).
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sing thFig. 6. Validation of computational procedure. Rescoring procedure by u
separate ligands (white bars) from decoys (gray bars).
Taken together these ﬁndings outline the existence
of several metabolic forms possibly able to interact with
serotonin receptors. Therefore the hierarchical screening
of the entire set of metabolites may  allow to proceed
with experimental trials exclusively on noteworthye software HINT allowed the proper clustering of compounds. Red lines
compounds. Also, the computed metabolites might be
actually accounted for the targeted detection in sam-
ples, thus concurring to further deﬁne the metabolic
pattern of ergotamine likely responsible for serotonergic
action.
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Fig. 7. Binding mode of ergotamine within 5HT-2B receptor. The protein is represented in ribbon, the binding pocket in yellow mesh and the ligand in
sticks.  The comparison between crystallographic data (white colored) and computed pose (yellow colored) is detailed in the side box.
Fig. 8. Structural basis of structure-speciﬁc interaction patterns. The binding sites are represented in surface while ligands and amino acids are represented
in  sticks. (A) G ring sub-site resizing between 5HT-2A (yellow surface on the left) and 5HT-2B (white surface on the right) due to G359Q mutation (highlighted
by  colored rings). The ligands predicted as able to interact with the respective models are reported. (B) Shape resizing at the bottom of the pocket (highlighted
by  blue ring) between 5HT-2A (yellow surface) and 5HT-2B (white surface). Ligands showing differential interaction are reported (CM-9 is colored in green,
a  moiety
i th 5HT-
i  preven
4
o
i
cnd  CM-12 is colored in blue, respectively). In 5HT-2B model, the ergoline
nteractions. (C) Effect of D147K mutation on the interaction of CM-1 wi
ndicates hydrogen bond. The presence of lysine-to-aspartate substitution
. DiscussionNowadays the presence of EAs in food and feed is
f growing concern and further data on toxicodynam-
cs and toxicokinetics, including metabolism, of the most
ommon EAs are needed, as recently stated by EFSA [7]. of both compounds is too close to pocket sides thus preventing favorable
2A (yellow surface) and 5HT-2B (white surface). The yellow dotted line
ts hydrophobic-polar interferences and gains further interaction.
The interaction with some neurotransmitter receptors
(including serotonin receptors) is a well-known mode of
action leading to a series of adverse effects on human
health. It is likely that EAs, as xenobiotics, undergo mas-
sive metabolic changes by hosts detoxifying mechanisms,
and their metabolites may  exert a certain bioactivity as
ology Re544 L. Dellaﬁora et al. / Toxic
well. Nevertheless, neither extensive studies on human
metabolism of EAs occurring in food (e.g. ergotamine), nor
the effect of metabolism on parent compound activity, are
systematically under study so far, also on account of the
efforts required for the a priori multi-receptors analysis
of metabolome activity. Actually, the existence of truly
detoxiﬁed forms and still active metabolites is largely over-
looked, and, consequently, the lack of knowledge in respect
to the consequences of metabolic modiﬁcations may  lead
to a deceptive scenario for risk assessment. Within this
framework, it has been assessed herein whether an in silico
analysis may  be an effective choice to analyze the interac-
tion between some members of serotonin receptors class
and ergotamine metabolites. The main goal was to provide
a fast and straightforward procedure to support and drive
the design of smart trials to support hazard characteriza-
tion. In this respect, it should be kept in mind that quantum
chemical approaches – which effectively address the cal-
culation of the Gibbs free energy alongside geometrical
aspects of complex formation – have been successfully
applied to the rational design of ergoline-based chemicals
[38], also against 5HT-2A [17]. Nonetheless, in the case of
virtual screening of wide datasets of compounds, the use
of such methods may  be challenging and demanding, espe-
cially in terms of hardware requirements. For this reason,
the use of a validated molecular mechanic approach based
on docking–rescoring coupling – which takes advantage of
an empirical scoring function – was a less demanding and
easy to implement choice. Hence, since the EA-serotonin
receptor interaction is at the basis of the molecular initi-
ating event of EAs action, and 5HT-2B three-dimensional
structure was available in Protein Data Bank, a 3D molec-
ular modeling approach based on docking simulations and
re-scoring procedure has been successfully used.
Validating procedures assessed the reliability of 5HT-2A
and 5HT-2B models to be applied to a set of ergo-
tamine metabolites. Notably, such set comprised both
experimentally detected compounds and purely computed
metabolites. The study was mainly aimed at investigat-
ing how metabolism can plausibly affect the bioactivity.
According to previous studies, the activity of hydroxylated
metabolites was conﬁrmed, although the output suggests
certain receptor speciﬁcity. The reduction of available vol-
ume  due to G359Q mutation at the level of the sub-site for G
ring might reduce the interaction with 5HT-2B for the most
of hydroxylated metabolites in the G ring. In this regard,
one has to keep in mind that, when homology relation-
ship subsists, sequence and structure similarities are key
conditions at the basis of functional inference of proteins
[39]. Therefore the residues conservation in key locus for
protein function plausibly determines functional conser-
vation. For this reason, albeit 5HT-2C model was rejected,
it can be hypothesized a behavior similar to 5HT-2B since
at such locus both held comparable bulky side-chains (i.e.
glutamate and asparagine, respectively). On the contrary,
at the level of tolerance of modiﬁcations on ergoline moi-
ety, it can be supposed a 5HT-2A-like behavior due to the
occurrence of the same M218V mutation (Fig. 4).
With respect to conjugated derivatives, none of the
glycosylated compounds seemed to be able to interact
with 5HT-2A and 5HT-2B models, supporting thus noports 2 (2015) 535–545
bioactivity. On the basis of the conservation of the over-
all anatomy of the pocket, we could postulate the lack
of interaction with 5HT-2C, as well. Being the detoxiﬁca-
tion of contaminated food and feed a paramount task [40],
this ﬁnding can be transferred to that context, taking into
consideration that any conjugation of a polar and bulky
group that originates from technological treatment of raw
materials or from metabolic transformations may  signif-
icantly reduce the serotonergic action of EAs. Notably, no
signiﬁcant contributions to the interaction were charged on
modiﬁcations on G ring. Those were rather tolerated when
the reduction of interferences was  possible. This ﬁnding
might be taken into account to conceive inactivating mod-
iﬁcations. Contrariwise several of computed modiﬁcations
brought further interactions. In particular CM-3, CM-4, CM-
6, CM-7, CM-13 gained further hydrogen-bonds with both
models, while CM-2 with 5HT-2B only (data not shown).
For the rest of metabolites predicted as able to interact, it
is concluded that modiﬁcations did not interfere in a large
extent to the pockets, thus allowing the interaction with
the binding site.
Strikingly, it is worthy of note that more than two-thirds
of metabolites herein considered were predicted as active.
Therefore, taken altogether, our ﬁndings ultimately suggest
the need for further data on serotonergic activity of ergo-
tamine’s metabolites, which might actually elude in some
extent, at least, the phase I detoxifying pathway.
5. Conclusions
Summarizing, in the present paper the in silico mod-
eling proved to be an effective choice to investigate the
interaction of ergopeptine alkaloids derivatives with mul-
tiple serotonergic receptors. Moreover, to the best of our
knowledge, such a wide array of human metabolites of
ergotamine has been taken into consideration for the ﬁrst
time. Models for 5HT-2A, 5HT-2B and 5HT-2C were pro-
vided, and albeit the last was not validated, it was possible
to outline possible guidelines for future experiments on the
basis of sequence conservation and structural analogies.
This work actually represents a knowledge-based, straight-
forward and cost effective choice to provide the priority
setting of compounds before bench analysis, as the lack
of commercially available compounds prevents from sys-
tematic trials on multiple serotonergic receptors. On the
condition that a sufﬁcient system of background knowl-
edge subsists for design and assessing the model – so as
to deﬁne the domain of applicability unequivocally – this
approach may  be extended to any toxicant of interest in
food toxicology, offering thus a useful strategy to support
hazard identiﬁcation at an early stage.
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